Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
NCT07670156Phase 2Not yet recruiting
- Sponsor
- Lisa Satter
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib in JAK-STAT pathway disorder, sponsored by Lisa Satter. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
JAK-STAT pathway disorder
Beyond the preview
Go deeper on NCT07670156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670156.